Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Lindbrook Capital LLC

Lindbrook Capital LLC lessened its holdings in Becton, Dickinson and Company (NYSE:BDX) by 11.3% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 918 shares of the medical instruments supplier’s stock after selling 117 shares during the period. Lindbrook Capital LLC’s holdings in Becton, Dickinson and Company were worth $224,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in shares of Becton, Dickinson and Company by 2.0% in the third quarter. Vanguard Group Inc. now owns 25,927,519 shares of the medical instruments supplier’s stock worth $6,703,041,000 after acquiring an additional 516,427 shares during the period. Morgan Stanley grew its position in Becton, Dickinson and Company by 4.5% during the 3rd quarter. Morgan Stanley now owns 10,200,213 shares of the medical instruments supplier’s stock worth $2,637,062,000 after purchasing an additional 435,168 shares during the period. Massachusetts Financial Services Co. MA raised its stake in shares of Becton, Dickinson and Company by 11.0% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,192,832 shares of the medical instruments supplier’s stock valued at $1,342,503,000 after buying an additional 512,566 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Becton, Dickinson and Company by 10.9% in the 3rd quarter. Bank of New York Mellon Corp now owns 4,034,523 shares of the medical instruments supplier’s stock valued at $1,043,045,000 after buying an additional 395,657 shares during the period. Finally, Ameriprise Financial Inc. grew its holdings in Becton, Dickinson and Company by 9.2% during the third quarter. Ameriprise Financial Inc. now owns 3,630,351 shares of the medical instruments supplier’s stock worth $938,593,000 after acquiring an additional 304,629 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the transaction, the senior vice president now owns 2,276 shares of the company’s stock, valued at $542,348.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.31% of the stock is currently owned by insiders.

Becton, Dickinson and Company Trading Down 0.1 %

Shares of NYSE:BDX opened at $233.88 on Tuesday. The business’s 50 day moving average price is $239.81 and its 200-day moving average price is $241.99. Becton, Dickinson and Company has a 1 year low of $229.40 and a 1 year high of $287.32. The firm has a market capitalization of $67.57 billion, a price-to-earnings ratio of 55.42, a price-to-earnings-growth ratio of 1.93 and a beta of 0.43. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.08 and a quick ratio of 0.64.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.39 by $0.29. The business had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.73 billion. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The company’s revenue was up 2.6% compared to the same quarter last year. During the same period last year, the firm posted $2.98 earnings per share. On average, equities research analysts forecast that Becton, Dickinson and Company will post 12.94 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Barclays boosted their price target on Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an “overweight” rating in a report on Monday, February 5th. Raymond James increased their price target on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $280.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.